Halozyme Therapeutics (HALO) EBT: 2009-2025
Historic EBT for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $219.0 million.
- Halozyme Therapeutics' EBT rose 32.58% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $745.9 million, marking a year-over-year increase of 55.37%. This contributed to the annual value of $557.1 million for FY2024, which is 59.94% up from last year.
- According to the latest figures from Q3 2025, Halozyme Therapeutics' EBT is $219.0 million, which was up 6.84% from $204.9 million recorded in Q2 2025.
- Over the past 5 years, Halozyme Therapeutics' EBT peaked at $219.0 million during Q3 2025, and registered a low of $28.1 million during Q1 2021.
- In the last 3 years, Halozyme Therapeutics' EBT had a median value of $117.7 million in 2024 and averaged $133.9 million.
- Per our database at Business Quant, Halozyme Therapeutics' EBT surged by 561.03% in 2021 and then slumped by 67.21% in 2022.
- Quarterly analysis of 5 years shows Halozyme Therapeutics' EBT stood at $54.8 million in 2021, then increased by 29.16% to $70.8 million in 2022, then skyrocketed by 42.92% to $101.2 million in 2023, then surged by 76.14% to $178.2 million in 2024, then spiked by 32.58% to $219.0 million in 2025.
- Its last three reported values are $219.0 million in Q3 2025, $204.9 million for Q2 2025, and $143.8 million during Q1 2025.